FINWIRES · TerminalLIVE
FINWIRES

Nxera Pharma Partner Neurocrine Biosciences Doses First Patient in Phase 2 Schizophrenia Study

-- Nxera Pharma (TYO:4565) said its partner Neurocrine Biosciences has dosed the first patient in a mid-stage trial of an experimental schizophrenia treatment, triggering a $22.5 million milestone payment to the Japanese drugmaker, according to a Monday filing on the Tokyo Stock Exchange.

The Phase 2 study will evaluate NBI-1117570, an oral dual muscarinic M1/M4 receptor agonist discovered by Nxera, in adults with schizophrenia requiring in-patient care. The payment will be booked as revenue in the first quarter of fiscal 2026, Nxera said.

The randomized, double-blind, placebo-controlled trial is expected to enroll about 120 patients. Its main goal is to measure changes in the Positive and Negative Syndrome Scale (PANSS) total score, a standard tool used to assess symptom severity, while also tracking safety and tolerability.

NBI-1117570 targets muscarinic acetylcholine receptors in the brain, with M1 linked to cognitive function and M4 associated with psychosis. The compound was developed using Nxera's NxWave drug discovery platform and is being advanced under a multi-program partnership with Neurocrine.

Related Articles

Equities

Eni Boosts Buyback, Cash Flow Guidance Amid Sustained Operational Growth Expectations in 2026

Eni (ENI.MI) significantly increased its proposed share buyback and lifted its cash flow guidance by 20% for 2026, supported by "strong" underlying financial performance in the first quarter amid energy market disruptions and volatility in commodity prices.The Italian energy group on Friday reported a total revenue of 20.06 billion euros for the three months ended March 31, up from 19.19 billion euros a year before. Sales from operations also rose over the period to 22.96 billion euros from 22.57 billion euros.Adjusted net profit attributable to shareholders, on the other hand, declined to 1.30 billion euros from 1.41 billion euros, weighed down by a lower tax rate due to a better geographical mix of profits before taxes in the exploration and production segment.Analysts at RBC Capital Markets described Eni's first-quarter results as "mixed" but noted the group's continued operational momentum."Looking forward, thanks to our high-quality and diversified asset portfolio, providing us with significant flexibility, E&P low breakeven prices and resilient financial structure, with gearing at historic lows, we are uniquely positioned to capture scenario improvements and to share expected upside with shareholders," Chief Executive Officer Claudio Descalzi said in an earnings release. "Our new cash flow guidance of EUR13.8 bln at a revised scenario for the FY '26 reflects this and will translate into an expanded buyback program of EUR2.8 bln, almost a 90% increase vs the original plan."In terms of dividends, the group confirmed its planned dividend of 1.10 euros per share for 2026, up 5% from the previous year. It also expects to see continued operational growth and cash flow generation during the current financial year."Eni has raised its [Global Gas & LNG Portfolio] guidance today to EUR1.3bn, a 30% uplift from its original guidance. Given gas market dynamics, we think this is largely expected, however Eni has a history of multiple nudges up in guidance through the year, and so we think investors will start to anticipate another uplift if the situation in the Middle East persists and gas markets stay volatile," the research firm said.Eni's shares were trading almost 1% higher in Milan as of midday Friday.

$ENI.MI
Asia

HD Renewable Energy Plans Private Placement of Up to 15 Million Shares

HD Renewable Energy (TPE:6873) plans to undertake a private placement of up to 15 million shares, according to a Friday Taiwan Exchange filing.The placement will be offered to selected investors to be identified later, according to a Friday Taiwan Exchange filing.The issue price will be set at no less than 80% of a benchmark market price, subject to shareholder approval, it said.Proceeds will be used to bolster working capital, improve efficiency, and enhance competitiveness, while reinforcing the group's financial structure.

$TPE:6873
Asia

Hyundai Rotem's Net Attributable Income Jumps 27% in Q1

Hyundai Rotem (KRX:064350) posted first-quarter net income attributable to shareholders of 201.4 billion won, up 27% from 158.4 billion won a year earlier, according to a Friday filing with the Korea Exchange.The South Korean defense products and equipment maker's sales jumped 24% year over year to 1.457 trillion won from 1.176 trillion won.Shares of Hyundai Rotem fell 1% at market close.

$KRX:064350